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Prrhythmia Predisposition
etween Rare Disease Paradigms
nd Common Ion Channel Gene Variants
ric Schulze-Bahr, MD*†‡
ünster, Germany
Cardiac side effects, such as QT prolongation or occurrence of Torsade de pointes (TdP),
from widely used cardiac and non-cardiac drugs are still a major challenge for physicians.
Recent advances in knowledge on the physiology of myocardial repolarization have made it
clear that alterations of ion channel genes are associated with diverse in vitro effects that may
tune normal repolarization to critical edges where ventricular arrhythmia occurs. The extent
to which genetic factors (aside from “typical” ion channel gene mutations) are associated with
susceptibility to TdP remains to be determined and is addressed in this review. Future
research must: 1) identify all relevant genes for repolarization; 2) determine the extent to
which the variability of the QT interval and of the response to action potential prolongation
is genetically controlled; 3) investigate the role of functionally relevant single nucleotide
polymorphisms/haplotype constellations to the contribution to repolarization; and 4) inte-
grate identified genetic factors with other known factors for TdP risk, according to their
relative importance, in a network algorithm for arrhythmogenesis. Gaining an understanding
of the current genetic and genomic data of patients with drug-induced arrhythmia are the first
steps to overcoming the hurdles associated with unexpected cardiac side effects of a variety of
drugs. (J Am Coll Cardiol 2006;48:67–78) © 2006 by the American College of Cardiology
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.006Foundation
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ahenotypic variation in arrhythmia development is well
nown from families with inherited, arrhythmogenic disor-
ers and also from patients with polygenic disorders, e.g.
yocardial infarction, for which not every patient develops
entricular fibrillation during acute ischemia. Multiple fac-
ors, such as age, gender, and environmental conditions,
lay an important role in the modulation of the phenotype.
he extent of genetically controlled variation is not clear to
ate, but it is of potential interest. Knowledge of contrib-
ting factors may be generally useful for addressing arrhyth-
ia susceptibility independently of its cause and may
ecome a (laboratory) tool for risk stratification. Recently,
ommon protein variants in cardiac ion channels have been
dentified that may have a potential impact on arrhythmia
usceptibility and pharmacogenetic strategies for arrhythmia
ircumvention and therapy. It is currently being investigated
hether these gene variants help to explain the individual
ifferences in arrhythmia development. The characteriza-
ion of single gene disorders, which is still incomplete, has
rovided important insights into the molecular pathogenesis
f cardiac arrhythmias. Emerging data on genotype/
henotype relations already exists and led to clinically
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ccepted May 1, 2006.elevant recommendations for gene-specific management of
atients. Early genotyping now enables the identification of
atients at high cardiac risk in a familial setting. In this
eview, the impact of common ion channel gene variants on
cquired arrhythmogenic conditions is reviewed.
NHERITED ARRHYTHMOGENIC
ISORDERS AND ION CHANNEL GENES
Primary electrical heart disease” refers to a group of rare,
ften familial, cardiac arrhythmias, in the absence of struc-
ural heart abnormalities. These disorders are mostly, but
ot exclusively (1–3), associated with mutations in cardiac
on channel genes. The long-QT syndrome (LQTS),
hort-QT syndrome (SQTS), Brugada syndrome (BrS), and
atecholaminergic polymorphic ventricular tachycardia
CPVT) belong to this group. Together they account for 5%
o 10% of sudden cardiac death (SCD) victims, and even
ore among the young (4–8). The population frequency of
ach arrhythmogenic disorder in the general population is
ot exactly known, but it is about 1 in 5,000 people for
QTS (9) and less for BrS (10–14). No information
urrently exists for CPVT and SQTS, but these disorders
ay have a significant contribution to idiopathic ventricular
brillation (15,16). Recently, the term “electrical heart
isease” came under discussion, as patients of these disor-
ers were found to exhibit structural heart abnormalities
17–21,22). In the past, case reports already indicated,
efore the era of genetic testing, that structural changes may
ccur (23–27). Because not all SCD victims show structural
bnormalities postmortem (e.g., sudden infant death syn-
rome cases), it may be true that some structural abnormal-
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Genetics of Arrhythmia Predisposition November 7, 2006:67–78ties may occur as a consequence of aging (28). Therefore,
hese disorders are also classified as having “no apparent
eart disease” (29) or as “ion channel cardiomyopathies”
30); exact nomenclatures will be addressed in future inves-
igations.
Important insights into the pathogenesis of cardiac ar-
hythmias have been achieved from the molecular charac-
erization of monogenic inherited arrhythmia syndromes
Table 1). The ion channel basis of congenital LQTS was
iscovered over 10 years ago by disease-causing mutations in
he KCNH2 gene (HERG) and SCN5A (Nav1.5), which are
he genes encoding the cardiac delayed rectifier IKr potas-
ium and INa sodium currents, respectively. Congenital
QTS is characterized by prolonged ventricular repolariza-
ion on the surface electrocardiogram (ECG) (i.e., QT
rolongation) and ventricular tachyarrhythmias. Syncope
nd sudden death in LQTS patients may result from a
istinctive polymorphic ventricular tachycardia (VT) called
Torsade de pointes” (TdP). Later, further heterogeneity of
QTS was shown by detecting mutations in the delayed
ectifier IKs potassium channel gene KCNQ1 (31,32) and
he 2 genes for the small beta subunits KCNE1 and
CNE2 (33–37). Detailed reviews can be found elsewhere
38,39). A list of the more than 300 published LQTS
utations, which are more or less “private” (family-specific),
nd identified gene polymorphisms can be obtained on
everal web sites. In addition to these subforms, 3 related
isorders with an extracardiac phenotype due to pleiotropic
ene effects are known (Jervell and Lange-Nielsen syn-
rome, Andersen-Tawill syndrome, and Timothy syn-
rome) (32,36,40,41).
An unexpected phenotype complexity has been noted
hat gives patterns of “polygenic” (multifactorial) disease to
nherited arrhythmia syndromes. This may be a result of
ultiple interactions of a gene mutation with individual or
nvironmental factors or with modifier genes or gene
ariants. This interplay is thought to alter the expressivity of
specific phenotype from mild to pronounced even in
arriers of the same mutation. As an example, cardiac
odium channelopathies (families with SCN5A mutations)
how a broad, complex genotype-phenotype variety in the
ame family (i.e., members with an identical mutation),
Abbreviations and Acronyms
BrS  Brugada syndrome
CPVT  catecholaminergic polymorphic ventricular
tachycardia
HERG human ether-a-go-go gene
I  ionic current
LQTS  long-QT syndrome
SCD  sudden cardiac death
SNP  single nucleotide polymorphism
SQTS  short-QT syndrome
TdP  Torsade de pointes
VT  ventricular tachycardiahich leads to overlap syndromes or distinct clinical entities p42–45). Such studies highlight the hazards of predicting
henotype on the basis of gene mutations alone. Current
fforts in risk stratification of these arrhythmia disorders
46–50) are on the way, but genetic and pathophysiological
eterogeneity often make a clear correlation with clinical
utcome difficult and less linear than anticipated.
CQUIRED VENTRICULAR
RRHYTHMIAS AND IONIC CURRENTS
cquired monomorphic and polymorphic VTs are more
requent and typically occur in the context of structural heart
isease. Among all the possible factors, various triggers may
etermine arrhythmia susceptibility, but the role of genetic
actors is probably small when there is no evidence for a
onogenic cardiac disorder. Population-based studies still
emonstrated an increased risk of SCD among patients
ith a parental history of cardiac arrest (8), but the genetic
asis is not yet clear. Very recently, a quantitative influence
n the myocellular repolarization due to (yet unidentified)
enetic variation at several chromosomal loci has been
escribed (51,52). Moreover, other risk factors (e.g., struc-
ural and electrical remodeling during acute ischemia, al-
ered hemodynamic loads, or changes in neurohormonal
ignaling) are recognized key features that alter ion channel
ene expression. Down-regulation of major repolarizing
otassium currents, Ito, IKr, IKs, and IK1, has been described
n several models of heart failure and resembles a condition
f “acquired QT prolongation.” Cellular abnormalities
hrough disturbances in the electrical cell-cell coupling and
local reduction of conduction velocity facilitate re-entrant
entricular arrhythmias. These cellular abnormalities can be
ound in the structurally diseased heart.
Drug-induced LQTS is another serious but reversible
orm of an acquired repolarization disturbance. The diag-
osis depends upon demonstrating a significant prolonga-
ion of the QT interval during drug exposure and an
xclusion of other causes of ventricular arrhythmia (e.g.,
erum potassium 2.5 mmol/l, acute coronary ischemia,
tructural heart disease). The QT interval prolongation
xtends to excessive values (more than 60 ms); it appears
ith T-wave lability/alternans and changes in T-wave
orphology (negative or notched/biphasic), prominent
T)U waves, or marked increase in QT interval dispersion.
his serious, adverse reaction to drug exposure is often
ccompanied by TdP and has led to several post-marketing
ithdrawals of drugs (e.g., terodiline in 1991, terfenadine in
998, or levomethadyl recently). The incidence of drug-
nduced TdP is estimated to be at least 10 per million per
ear in Sweden (46). It is estimated that only a small
raction of these cases were recognized and reported. Other
stimates based on prescription data suggest that exposure
f 1% of the population to a torsadogenic drug doubles the
isk ration for SCD and would account for about 10 deaths
er million per year (53).
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November 7, 2006:67–78 Genetics of Arrhythmia PredispositionPathophysiologically, the hallmark mechanism of drug-
nduced LQTS is the blockade of the IKr channels (54–56),
hich are encoded by human ether-a-go-go gene (HERG),
he LQT2/SQT1 gene (57,58). This affinity is due to 2
mportant structural characteristics: first, a larger inner
avity of IKr channels than that of any other voltage-gated
 channel, and second, a transmembranous (so-called
6) domain that has 2 aromatic residues at the cytosolic
able 1. Cardiac Ion Channel Disorders
Gene Symbols Chromosomal Locus Protein
CNQ1 11p15.5 Potassium channel
-subunit (KvLQ
CNH2 (HERG) 7q35-q36 Potassium channel
-subunit
CN5A 3p24-p21 Sodium channel ge
-subunit (hH1)
CNE1 21q22 Potassium channel
-subunit (minK
CNE2 21q22 Potassium channel
-subunit (MirP
CNJ2 17q23 Potassium channel
ACNA1c 12p13.3 Calcium channel g
nkB 4q25-q27 Anchoring protein
linking integral
membrane prote
spectrin-actin
cytoskeleton
yR2 1q42.1-q43 Cardiac ryanodine
receptor
ASQ2 1p13-p11 Calsequestrin
CN4 15q24-q25 Cation channel gen
FiB  atrial fibrillation; AStSt  atrial standstill; AVB  atrioventricular block; B
nsP3R  ionositol-1,4,5-phosphate-receptor; IVF  idiopathic ventricular fibrillatio
sinus bradycardia; SIDS  sudden infant death syndrome; SQTS  short-QT syite to bind larger, aromatic drugs. Some exceptions of gon-IKr blocking drugs (e.g., arsenic trioxide or indapam-
de) with observed TdP exist. An IKr blockade prolongs the
yocardial action potential, preferentially in the mid-layer
ells and Purkinje fibers rather than in other tissue layers,
ecause the former have lower IKs and higher INa and thus
esult experimentally in an increase of QT dispersion
59,60). The IKr blocking drugs usually demonstrate a
everse frequency-dependent effect. The degree of prolon-
Physiological Function
Inherited Disorder,
Mode of Inheritance
Myocellular repolarization
(IKs current)
LQT1 (autosomal dominant or
recessive  inner ear
deafness, sporadic, acquired)
SQT2 (sporadic)
AFib (autosomal dominant)
SIDS (sporadic)
Myocellular repolarization
(IKr current)
LQT2 (autosomal dominant or
recessive, sporadic, acquired)
SQT1 (autosomal dominant,
AFib)
BrS2 (sporadic)
Myocellular
depolarization (INa
current)
LQT3 (autosomal dominant or
recessive, sporadic, acquired)
BrS1 (autosomal dominant)
(P)CCD (autosomal dominant)
AVB (sporadic)
AStST (autosomal dominant)
SIDS (sporadic)
Myocellular repolarization
(IKs current)
LQT5 (autosomal dominant or
recessive  inner ear
deafness)
Myocellular repolarization
(IKr current)
LQT6 (autosomal dominant or
sporadic)
Maintenance of resting
potential, terminal
repolarization (IKir
current)
LQT7 (autosomal dominant or
sporadic)
Myocellular
depolarization (IL, Ca
current)
LQT8 (autosomal dominant or
sporadic)
Disruption or cellular
organization; reduced
protein levels of NCX,
Na/K-ATPase, and
InsP3R; altered Ca
2
signaling
LQT4 (autosomal dominant,
AFib)
Ca2 release channel of
endoplasmic reticulum
(electromechanical
coupling)
CPVT (autosomal dominant,
sporadic)
IVF (sporadic)
Ca2 storage protein of
endoplasmic reticulum
(electromechanical
coupling)
CPVT (autosomal recessive)
Spontaneous diastolic
depolarization (If
current)
SBr (sporadic, familial)
rugada syndrome; CPVT  catecholaminergic polymorphic ventricular tachycardia;
TS  long-QT syndrome; (P)CCD  (progressive) cardiac conduction disease; SBr
e.gene,
T1)
gene,
ne,
gene,
)
gene,
)
gene
ene
ins to
e
rS  Bation in action potential duration is more prominent
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Genetics of Arrhythmia Predisposition November 7, 2006:67–78uring a low heart rate, when the QT interval is longer.
oreover, concentration-dependent effects on the prolon-
ation of the QTc interval are known for many drugs, with
he exception of quinidine. Important co-factors for TdP
evelopment during drug IKr blockade are hypokalemia,
ypomagnesemia, hypertrophy, and heart failure, all of
hich prolong the baseline action potential duration by
educing major repolarizing potassium currents. Gender is
lso another important modulating factor, for women have
onger QT intervals and a greater propensity for drug-
nduced TdP (61–66), due to differences in the densities of
Kr and IK1 currents but not of IKs and Ito. In contrast, men
ith BrS were reported to have a much more prominent Ito
n the right ventricle (67).
OMMON ION CHANNEL GENE VARIANTS
he “rare disease paradigm” refers to the common hypoth-
sis that genetic mutations for Mendelian disorders are rare
n the general population and that these disorders have a low
ncidence because genetic mutations for Mendelian disor-
ers are rare in the general population. Systematic sequenc-
ng of genes for rare arrhythmogenic disorders has shown to
arbor a significant portion of “natural variance” (polymor-
hic sites, single nucleotide polymorphisms [SNPs]), which
re assumed to alter the protein structure (non-synonymous
hanges). The idea that this “common genetic variance” may
etermine common phenotypes has expanded to more
ommon arrhythmias. Research groups are currently trying
o correlate SNP in ion channel genes with polygenic
rrhythmogenic disorders (e.g., atrial fibrillation). All types
f polymorphic sites were found in ion channel genes. They
iffer from their location within the genomic sequence
able 2. Types and Sequence Location of DNA Variation (70)
Polymorphism Type Sequence Location and
onsense Coding Prem
los
issense, non-synonymous Coding, non-conserved Alter
sim
issense, non-synonymous Coding, conserved Alter
dif
earrangements
(insertion/deletion)
Coding Alter
dif
ense, synonymous Coding Unch
an
romoter and regulatory sequences Non-coding, promoter/
UTR
Unch
ma
ntronic nucleotide exchange
(40 bp)
Non-coding, splice/
lariat sites
Alter
rec
ntronic nucleotide exchange
(40 bp)
Non-coding, between
introns
Unch
ab
ins
rea
ntergenic nucleotide exchange Non-coding, between
genes
Unch
eff
gro
p  base pairs; UTR  untranslated region (5= or 3= region of a gene).coding vs. non-coding areas), from the type of nucleotide (xchange and the consequence for the amino acid sequence,
nd from the frequency (relative occurrence) in the human
enome (Table 2). Polymorphisms with the potentially
ighest phenotypic disease impact are rare within the
enome. For genetic association studies, more frequent
olymorphisms (e.g., missense/non-synonymous or sense/
ynonymous) are used and require large case and control
opulations, because of the low phenotypic impact. Pro-
osed guidelines have been developed that should facilitate
he quality of association studies (68,69), including strate-
ies to ascertain heritability and exact phenotyping of a trait,
o perform population stratification of cases and controls
ethnicity, age, and gender distribution), to select physiolog-
cally and genetically meaningful markers, to address the
robability of association, and to replicate initial results in
ndependent studies. To date, only a few of the several
housand published association studies strictly meet criteria
o ascertain a (“true”) genetic association. For arrhythmo-
enic disorders, the majority of data are still unreplicated by
ndependent investigators or studies. The potential of ap-
lying new approaches, such as the evaluation of genomic
nformation or serial proteomic expression, is still difficult to
chieve in practice. Differences in study outcome may be
elated to population stratification, study design, still inap-
ropriate marker selection, and lack of statistical power (70).
iscovery of meaningful SNP markers (e.g., indicating an
levated risk of SCD) is still far from being established.
The idea that common ion channel sequence variance
ay also contribute to a common arrhythmia and SCD
usceptibility was driven by the identification of non-
ynonymous protein alterations and in vitro characterization
howing subtle alterations differing from the wild-type
redicted Protein
ntial Functional Effects
Occurrence
in Genome
Potential
Disease Impact
ly truncated, most likely
rotein function
Very low High
ino acid chain, mostly
rotein properties
Low Low (to high)
ino acid chain, mostly
protein properties
Low Medium to high
ino acid chain, mostly
protein properties
Low High
amino acid chain, rarely
on exon splicing
Medium Low (to medium)
amino acid chain, but
ct gene expression
Low to medium Low to high,
depending on site
ino acid chain, failed
ion of exonic structure
Low Low to high,
depending on site
amino acid chain, rarely
l splicing or mRNA
ty, site for gene
ements
Medium Very low
amino acid chain, may
ne expression, site for
rrangements
High Very lowP
Pote
ature
s of p
ed am
ilar p
ed am
ferent
ed am
ferent
anged
effect
anged
y affe
ed am
ognit
anged
norma
tabili
rrang
anged
ect ge
ss rea70–96). The details of ion channel gene SNPs are dis-
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November 7, 2006:67–78 Genetics of Arrhythmia Predispositionussed in detail elsewhere (70). Results of ion channel
lterations may be non-comparable or contradictory, be-
ause in-vitro experiments may not be standardized between
ifferent laboratories (73).
Ethnicity-specific and population-specific frequencies of
he SNP allele in ion channel genes must be taken into
ccount when performing association studies (71,72,
5,78,79,87,91,94,97–99). Researchers recently attempted
o link the SNPs of cardiac ion channel genes with the QT
nterval length in a Caucasian population (51). Using a
-step design (initial screen with many SNPs and a
edium-size population, successive screen with a few SNPs
ith suggestive linkage in a confirmatory sample), the SNPs
f 4 LQT genes (KCNQ1, KCNH2, KCNE1, and KCNE2)
ere investigated. A multivariate linear regression model
including heart rate, gender, and age as covariates) for QT
nterval calculation was developed (so-called QTc-RAS).
he SNPs in the KCNH2 (LQT2) and KCNQ1 (LQT1)
enes showed the strongest change on QTc-RAS (from
2.1 ms to 2.5 ms) when tested alone. When combining
NPs, quantitative additive effects were noted (e.g., for the
CNH2-K897T SNP (rs1805123). Previously, some
77,100), but not all, studies (87,95,101) suggested an effect
n the QTc interval duration. Although these results at first
uggest that myocardial repolarization is heritable as a
uantitive phenotypic trait, they, in fact, already show the
otential problems of association studies addressing the role
f certain SNPs on a quantitative trait.
ENETIC ASPECTS OF DRUG-INDUCED QT
ROLONGATION AND ECG PARAMETERS
everal studies have linked a prolonged, heart-rate adjusted,
T interval to an increased risk of cardiac death in patients
ith diseases other than LQTS and even in healthy indi-
iduals as well (102–106). The available studies on this are
ot consistent with each other (107,108). The occurrence of
cquired LQTS and TdP is often not predictable in indi-
idual patients. Acquired forms share clinical features with
he congenital variant of LQTS, and variants in genes for
ongenital LQTS have also been found in acquired LQTS
Table 3). Certainly, cardiac repolarization is modified by
any genetic and non-genetic factors, and thus arrhythmia
isk is polygenic, due to the combined influence of several
omponents. Sotalol testing (2 mg/kg body weight intrave-
ously) was able to unmask abnormal repolarization in
atients with diagnosed acquired LQTS. After infusion,
Tc increased moderately in controls (from 422 17 ms to
50  22 ms) but significantly in acquired LQTS subjects
from 434  20 ms to 541  37 ms) (109). Along these
ines, 56% to 71% of patients who suffer from TdP were
eported to have prolonged baseline QT intervals (110) and
T dispersion, compared with controls (e.g., when exposed
o dofetilide or almokalant) (111). In the relatives of
atients with acquired LQTS, intravenous quinidine signif-
cantly prolonged transmural dispersion of repolarization mTpeak-Tend interval), compared with the relatives of control
ubjects. Thus, it may indicate a heritable, but subtle,
omponent in repolarization capacity (112). Whether these
elatives are at risk for TdP development is not yet known.
t is though known from congenital LQTS that the clinical
rofile of a subject is not useful for determining the clinical
everity of other affected family members (113).
It is reasonable to assume that genetic factors modulate
usceptibility for TdP development and that ECG param-
ters have features of a quantitative genetic trait. It has
hough been found that only 10% to 15% of patients with
rug-induced LQTS carry variants in the coding regions of
he known LQTS genes (86,95,114) that cover disease
utations in 70% to 80% of the congenital forms. This may
till indicate an incompleteness of knowledge about the
enes or genomic constellations that predispose a person to
dverse drug reactions. A differentiation has been proposed
etween indirect, direct, and compound genetic effects, de-
ending on their interaction with IKr-blocking drugs (115).
ndirect effects of gene variants impair IKr channel function
t baseline but do not increase drug sensitivity, whereas
ompound effects refer to alterations of both. Direct effects
f LQTS variants are perhaps the most insidious variants, as
hey only increase sensitivity to drug blockade but cause no
etectable or significant in vivo or in vitro phenotype before
rug administration. In principle, the development of an
bnormal QT prolongation and an increase of the torsado-
enic potential may occur in a previously asymptomatic
atient with congenital LQTS, in which the diagnosis was
ot yet known or known without precise knowledge of the
rug’s action-potential–prolonging properties. The list of
rugs that prolong the QT interval and/or that were
ssociated with TdP is increasingly long. A more complex
ituation may occur when an LQTS gene mutation causes
nly subtle or no repolarization changes. Currently, reports
re available for genotype-phenotype data on the non-
enetrance of LQTS gene mutations. They suggest a
ignificant amount of incomplete penetrance (so-called
ilent mutation carriers with a normal QTc interval), rang-
ng from 10% (LQT3) through 19% (LQT2) up to 36%
LQT1) (46).
Despite that the majority of drugs associated with QT
rolongation bind particularly to IKr (HERG) channels,
utations in other than HERG have been described in
atients with drug-induced LQTS (114,116–118). This
as also reported for other proarrhythmic conditions such as
ypokalemia (119). Instead, mutations of LQTS genes for
hese patients have also been found in INa or IKs channel
enes (Table 3). These findings support the concept of the
repolarization reserve” (120), which refers to a variety of
actors that concordantly and critically impair repolarization
apacity toward the threshold for development of torsades.
t least 2 or more (repolarization-disturbing) hits are
nvolved (“multi-hit” hypothesis) (e.g., an LQTS gene
utation affecting repolarization [substrate] and drug-
ediated IKr inhibition [enhancer/modifier]). Often, a par-
TK
K
K
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Gene Current
Amino Acid
Alteration Drug/Setting Functional Assay Minor Allele Reference
CNE2 IKr T8E TMX/SMX; quinidine;
amiodarone
E8-MIRP1 weakly reduced IKr current
peak density; (CHO cells); SMX and
TMX had almost no effect on wild-
type channels, but SMX was
reported to inhibit more than 50% of
A8-MiRP1 at 40 mV; mutant
channels were 4 more sensitive to
SMX than wild-type
1.6% (34,86,89)
IKr Q9E Clarithromycin, low K
 Rare in Caucasians,
but not in
African
Americans
(34,71)
IKr M54T Procainamide T54-MiRP1 significantly reduced IKr
current peak density (CHO cells); no
influence on drug-related channel
inhibition was seen
Rare (89)
IKr M57T Oxatomide T57-MiRP1 significantly reduced IKr
current peak density (CHO cells); no
influence on drug-related channel
inhibition was seen
Rare (89)
IKr A116V Quinidine V116-MiRP1 significantly reduced IKr
current peak density (CHO cells); no
influence on drug-related channel
inhibition was seen
Rare (89)
CNH2 IKr M124T Probucol Co-expression of wild-type HERG and
T124-HERG resulted in markedly
smaller amplitudes of IKr (xenopus
oocytes); probucol decreased the
amplitude of the HERG tail current,
decelerated the rate of channel
activation, accelerated the rate of
channel deactivation, and shifted the
reversal potential to a more positive
value
Rare (137)
IKr R328C Not reported Rare (138)
IKr P347S Cisapride/clarithromycin Rare (86,139)
IKr R486H Quinidine Rare* (114)
IKr A561P Clobutinol P561-HERG led to an intracellular
trafficking defect; when co-expressed
with wild-type HERG, voltage-
dependence was shifted toward more
negative potentials (3–3.5 mV);
clobutinol further blocked
heteromeric channels
Rare* (140)
(141)
IKr R784W Amiodarone W784-HERG mediated a reduced IKr
current (by 75%) and a positive
shift of voltage dependence of
activation
Rare (95)
CNQ1 IKs R243H Halofantrine;
hydrochinine
Rare*† (114)
IKs Y315C Cisapride In-vitro expression of mutant KvLQT1
protein showed a severe loss of
current with a dominant negative
effect on the WT-KvLQT1 channel
Rare* (116)
IKs R555C Terfenadine Rare (117,142)
IKs R583C Dofetilide C583C-KvLQT1 mediated IKs was
reduced by 50% compared with
wild-type, and the voltage
dependence of activation was shifted
positively by 19.6 mV (CHO cells)
Rare (95)Continued on next page
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dentified that finally leads to the occurrence of TdP (121).
ther co-factors associated with a higher incidence of TdP
re hypokalemia, a slower heart rate (e.g., recent conversion
rom atrial fibrillation), pre-existing cardiac disease (hyper-
rophy, myocardial infarction), and female gender or base-
ine QTc intervals above 460 ms. Genetic susceptibility to
rug-induced LQTS has also been addressed for drug-
etabolizing genes, notably CYP2D6 and CYP3A4, as the
egree of QTc prolongation usually correlates with the
rug’s serum level (exception: quinidine) and its metabo-
ism. Thus, physicians need to be aware of some pharma-
odynamic and pharmacokinetic interactions to understand
he occurrence of potentially high concentrations. Genotyp-
zation of CYP2D6 is currently available to individualize the
osage of metabolized drugs (122), and this is important,
ecause of poor drug metabolization in 5% to 10% of
aucasians and African Americans. For CYP3A4, allelic
ariants are not consistently associated with drug metabo-
izing activity, and, therefore, genotyping has become less
elevant. In addition to inborn genetic variation, both
ytochromes may exhibit altered gene expression and activ-
able 3. Continued
Gene Current
Amino Acid
Alteration Drug/Setting
CN5A INa G615E Quinidine E
INa L618F Quinidine E
INa S1103Y Amiodarone Y
INa F1250L Sotalol E
INa P1825L Cisapride T
P1
Heterozygous mutation carriers may have a normal QT interval; for SCNSA, amin
rom recessive forms of LQTS.
CHO  Chinese hamster ovarian; HERG  human ether-a-go-go gene; LQTS
rimethoprim; TTX  tetrototoxin.ty in the context of other conditions (e.g., in the elderly, eith common food or co-administered drugs [e.g., eryth-
omycin and other macrolide antibiotics, ketoconazole and
ther azole antifungals, and mibefradil]) (123). Thus, phar-
acodynamic interactions (e.g., several QT prolonging
rugs) and pharmacokinetic interaction (e.g., with drug
learance of a QT prolonging drug) should be carefully
onsidered.
In acquired LQTS syndrome, efforts were focused on the
requency of LQTS polymorphisms, because mutations are
ot predominant. Yang et al. (95) screened the coding
egions of the 3 major LQT genes (LQT1-3) in 92 patients
ith drug-induced LQTS and additional controls. The
llele frequencies of 3 common, non-synonymous polymor-
hisms (SCN5A-H558R, SCN5A-R34C, HERG-K897T)
id not significantly differ between the 2 groups. Similar
ndings were reported by Paulussen et al. (86) and indicate
o particular concomitant effect of the presence of an LQTS
ene polymorphism and the occurrence of TdP. The role of
CNE2 (IKr beta subunit) variants in congenital and
rug-induced LQTS (34,89,95) is still under discussion, as
QT6 (KCNE2) mutations are rare in congenital LQTS
35,124,125) and may exhibit only subtle or no in vitro
Functional Assay Minor Allele Reference
CN5A indistinguishable from
type mediated INa currents (tsa-
ells)
Rare (95)
CN5A indistinguishable from
type mediated INa currents (tsa-
ells)
Rare (95)
SCN5A mediated an increased
hannel activation (HEK 293)
7%–10% (African
Americans or
West Africans/
Caribbeans only)
(95)
CN5A indistinguishable from
type mediated INa currents (tsa-
ells)
Rare (95)
terminal mutant P1825-
5A mediated INa current with
decay and prominent TTX-
sitive, non-inactivating
onent (gain-of-function), a
ed peak density (loss of
ion), shifted voltage dependence
tivation (more positive
tials) and of inactivation (more
ive potentials) (tsA-201 cells);
(118)
SCN5A channels showed
irment of intracellular trafficking
O cells) and failed to generate
rolongation; exposure with
ride rescued cell surface
ssion of P1825-SCN5A and
erating the LQT3 phenotype
(143)
residues are numerated according to positions on the long splice variant; †Reported
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CN5A) is another frequent LQT gene polymorphism that
s possibly related to drug-induced LQTS. It has been
dentified primarily in West Africans and Carribeans
around 19%) and in African Americans (around 13%) (91).
n contrast, it was not found in a sample of 511 Caucasians
nd 578 Asians, and it was rare in Hispanics (1 in 123) (91).
CN5A-Y1103 SNP was first identified in a 36-year-old
emale African American with idiopathic dilated cardiomy-
pathy, hypokalemia, and abnormal QT prolongation and
dP during amiodarone treatment. In the subject’s family,
he SCN5A-Y1103 allele was associated with a longer QT
nterval (YY carriers: QTc 464  22 ms, n  7; SY carriers:
Tc 458  22 ms, n  10; SS carriers: 415  24 ms, n 
0; p  0.0014, analysis of variance [ANOVA]), although
ost of the YY or SY carriers were asymptomatic and had
normal repolarization. The presence of another LQTS
ene mutation was not excluded. When 23 unrelated
arrhythmia cases” were investigated, a quantitative effect of
he Y1103 allele on the QTc interval was not seen (QTc: in
Y carriers 495  35 ms, n  2); in SY carriers 460  29
s, n  11; in SS carriers 453  44 ms (n  9  1); p 
.3570; ANOVA. Despite the fact that Y1103 allele carriers
YY or SY) had a higher relative risk for ventricular
rrhythmia occurrence (91), this observation was obviously
nlinked to baseline repolarization parameters. In-vitro
tudies demonstrated only subtle changes in INa channel
ctivation (increased activation, greater peak amplitude, and
arger sustained current) without a discernible effect on
imulated action potentials until an (drug-induced) IKr
lock was present (91).
Is the degree of heritability known for ECG parameters?
ery little data exist on this. Twin studies have been used to
xamine the effect of genetic variance on ECG parameters
129). PR interval, QRS duration, QRS axis, QTc, and
entricular rate were significantly determined by genetic
ffects, ranging from 30% to 60%. In another twin study,
usjahn et al. (127) showed in 100 healthy monozygotic
nd 66 healthy dizygotic twins that a significant portion
52%) of the variation of the QT interval was attributable to
enetic factors. Heritability was also found for the duration
f the P wave (46%) and for the QRS width (40%). Using
icrosatellite markers, QTc duration was quantitatively
etermined by the LQT1 and LQT4 loci, whereas QRS
nd T-wave axis appeared to be influenced by the LQT2
ocus (127). In addition, population-based studies such as
he National Heart, Lung, and Blood Institute Family
eart Study estimated the heritability of the QT interval
uration. Here, Hong et al. (128) found evidence of a major
enetic effect accounting for 11% of the variation in QT
nterval duration and multiple other effects accounting for
nother 34%. Similarly, Newton-Cheh et al. (52) found
5% heritability of QT interval duration. A genome-wide
inkage analysis reported suggestive evidence for linkage of
he QT interval to chromosome 3p (maximum multipoint
OD score of 2.84 at 24.4 cM). No linkages were found tonown ion channel genes, including SCN5A (LQT3) on
hromosome 3p, so the causal gene remains to be deter-
ined. All together there is broad evidence that QT interval
uration is a heritable trait in a complex genetic setting.
ONCLUSIONS AND FUTURE DIRECTIONS
ecent advances in knowledge of the physiology of myo-
ardial repolarization have made it clear that genetic alter-
tions of key molecular components, such as ion channels,
re associated with opposite in vitro effects of ionic current
egulation, which may tune normal repolarization to critical
dges where ventricular arrhythmia may occur (129). The
xtent to which genetic factors, aside from repolarization
typical” ion channel gene mutations, are associated with
usceptibility to TdP remains to be determined. It also
emains to be determined whether these are specific to
articular classes of drugs with a proarrhythmic propensity.
ollowing the concept of “repolarization reserve” (120), it is
ikely that TdP occurrence, upon an individual background
f a genetic predisposition, would be independent of specific
rugs and more linked to a drug’s propensity to alter
yocardial repolarization. As shown in Table 3, not only IKr
hannel gene mutations but also INa or IKs can be identified
n patients with drug-induced TdP and IKr channel block.
nimal models with chronic complete atrioventricular block
nd in-vitro studies have reported a high incidence of TdP
s a result of a significant down-regulation of both IKs and
Kr channels (130,131). Aiba et al. (132) showed that, in
ddition to drug-induced IKr channel block, subclinical IKs
ysfunction, mimicking KCNQ1 (LQT1) defects, could be
risk for drug-induced TdP, when other repolarizing
urrents such as IKr cannot maintain normal repolarization
apacity. Vice versa, IKs may function as a repolarization
eserve when the rapidly delayed rectifier IKr is reduced by
isease or drug. Thus, IKs can prevent excessive action
otential prolongation and development of early after-
epolarizations, which are precursors of TdP (133,134).
oreover, direct physical interactions between IKr and IKs
hannel subunits have been proposed (135,136); this would
ake considerations on the functional effects of LQT gene
utations or gene variants more complex than previously
nticipated.
For the comprehensive assessment of genetic factors in
rug-induced TdP, future research must:
Identify all relevant genes for repolarization, as the
portion of causative genes (e.g., for congenital LQTS), is
still incomplete;
Determine the extent to which the variability of the QT
interval and of the response to action potential prolon-
gation is genetically controlled;
Investigate the role of functionally relevant SNPs and
haplotype constellations in LQTS and other gene loci for
their quantitative contribution to repolarization; and
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factors for TdP risk, according to their relative impor-
tance, in a network algorithm for arrhythmogenesis.
he genetic and genomic understanding of drug-induced
rrhythmia is still in its infancy. For the majority of LQTS
NPs, valid, confirmatory data from independent genetic
ssociation studies are still lacking, and for some SNPs,
onflicting genetic and in vitro data have been reported.
here are still major hurdles to overcome (e.g., large,
owerful studies need to be performed [in various ethnic
roups]). Standardization of in vitro functional assessment
f non-synonymous SNPs is needed to compare lab-specific
esults. These data should be available within the next few
ears and advances, along with additional technological
mprovements, will enable researchers to lower the costs of
omplex genotyping. A major effort will be required from
cientists, physicians, and industry to overcome these hur-
les and to realize the concept of “the right drug for the
ight patient.”
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